MindWalk Holdings (HYFT) Asset Writedowns and Impairment (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Asset Writedowns and Impairment of $11.1 million for Q2 2024, up 237526.59% quarter-over-quarter from $4665.2 in Q3 2022.
MindWalk Holdings (HYFT) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Asset Writedowns and Impairment for 4 consecutive years, with $11.1 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Asset Writedowns and Impairment changed N/A year-over-year to $11.1 million; the TTM figure through Apr 2024 stood at $11.2 million (changed N/A YoY), while the FY2024 annual figure was $11.1 million, up 512.58% from the prior year.
- Asset Writedowns and Impairment improved to $11.1 million in Q2 2024 per HYFT's latest filing, from $4665.2 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $11.1 million in Q2 2024 and bottomed at -$34307.3 in Q2 2021.
- Historically, Asset Writedowns and Impairment has averaged $1.2 million across 4 years, with a median of -$16.7 in 2021.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment surged 99.86% — and 2022, when it jumped 557.4%.
- MindWalk Holdings' Asset Writedowns and Impairment stood at -$12101.3 in 2020, then soared by 99.86% to -$16.7 in 2021, then surged by 28028.09% to $4665.2 in 2022, then jumped by 237526.59% to $11.1 million in 2024.
- Business Quant data shows HYFT's Asset Writedowns and Impairment at $11.1 million in Q2 2024, $4665.2 in Q3 2022, and $127135.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -116,011.72 |
| Jan 31, 2026 | -116,011.72 |
| Apr 30, 2025 | -14.19 Mn |
| Apr 30, 2025 | -14.19 Mn |
| Jan 31, 2025 | 14.82 Mn |
| Jan 31, 2025 | 14.82 Mn |
| Apr 30, 2024 | 11.09 Mn |
| Apr 30, 2024 | 11.09 Mn |
| Jul 31, 2022 | 4,665.16 |
| Jul 31, 2022 | 4,665.16 |
| Apr 30, 2022 | 127,134.96 |
| Apr 30, 2022 | 127,134.96 |
| Jan 31, 2022 | 7,110.73 |
| Jan 31, 2022 | 7,110.73 |
| Oct 31, 2021 | -16.70 |
| Oct 31, 2021 | -16.70 |
| Jul 31, 2021 | -2,441.95 |
| Jul 31, 2021 | -2,441.95 |
| Apr 30, 2021 | -34,307.30 |
| Apr 30, 2021 | -34,307.30 |